组蛋白去乙酰化酶在肺动脉高压中的作用研究进展  

Research progress on the effect of histone deacetylase on pulmonary arterial hypertension

作　　者：王丹[1,2] 李芳伟[1] 万毅新[1] Wang Dan;Li Fang-Wei;Wan Yi-Xin(Respiratory Department,the Second Hospital of Lanzhou University,Lanzhou 730030,China;Respiratory Deparment,the Second Clinical Medical College of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院呼吸科,兰州730030 [2]兰州大学第二临床医学院呼吸科,兰州730030

出　　处：《解放军医学杂志》2022年第2期192-196,共5页Medical Journal of Chinese People's Liberation Army

基　　金：国家自然科学基金(81960014)。

摘　　要：肺动脉高压(PAH)是一种预后不良的进展性疾病,可导致右心功能不全,从而引起一系列临床症状,甚至导致死亡,目前尚缺乏有效的治疗方法。表观遗传改变在PAH的发病中起着重要作用。组蛋白乙酰化修饰是目前研究最为广泛和深入的表观遗传修饰之一。组蛋白乙酰化水平主要由组蛋白乙酰基转移酶(HATs)和组蛋白去乙酰化酶(HDACs)调节,在染色质和基因调控中发挥关键作用,与PAH的发生密切相关,且靶向组蛋白乙酰化途径对PAH有一定的治疗潜力。本文就HDACs在PAH中的作用研究进展进行综述,以期加深对PAH发病机制的了解,并为其治疗提供新的方向。Pulmonary arterial hypertension (PAH) is a progressive disease with poor prognosis,which may lead to right heart dysfunction,resulting in a series of clinical symptoms and even death,and there is still a lack of effective treatment.The etiology of PAH is complex,in which epigenetic changes play an important role?in its pathogenesis.Histone acetylation modification is one of the most widely and deeply studied epigenetic modifications.The histone acetylation is mainly regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs),which play a key role in chromatin and gene regulation,and is closely related to the occurrence of PAH.Targeted histone acetylation pathway has a certain therapeutic potential for PAH.This article reviews the research progress on the effect of HDACs on PAH,in order to further understand the pathogenesis of PAH and provide a new direction of treatment.

关 键 词：组蛋白去乙酰化酶 肺动脉高压 组蛋白去乙酰化酶抑制剂 表观遗传改变 组蛋白修饰 

分 类 号：R563.9[医药卫生—呼吸系统]